doi: 10.1002/1097-0142(197802)41:2<761::aid-cncr2820410250>3.0.co;2-2.
Reserpine and breast cancer
- PMID: 630550
- DOI: 10.1002/1097-0142(197802)41:2<761::aid-cncr2820410250>3.0.co;2-2
Item in Clipboard
Reserpine and breast cancer
Cancer.
1978 Feb.
Abstract
After a series of studies on the linkage of reserpine with breast cancer, both evidence and interpretation appeared to be in conflict. Our case-control survey of long-term, comprehensive records from the Kaiser Foundation Medical Care Program, on 108 hypertensive breast cancer cases and 324 hypertensive controls, matched by year of birth and by race, produces a significant positive association between reserpine use and breast cancer. However, the association vanishes upon further matching with respect to the year of the first hypertension diagnosis and the subsequent length of follow-up. We thus fail to support suspicions of causality.
Similar articles
-
Matched-pairs study of reserpine use and breast cancer.Lancet. 1975 Aug 16;2(7929):296-300. doi: 10.1016/s0140-6736(75)92731-2. Lancet. 1975. PMID: 50508
-
Exclusion bias and the false relationship of reserpine and breast cancer.Arch Intern Med. 1985 Oct;145(10):1873-5. Arch Intern Med. 1985. PMID: 4037948
-
Rauwolfia derivatives and breast cancer.Johns Hopkins Med J. 1976 Aug;139(2):41-50. Johns Hopkins Med J. 1976. PMID: 957533
-
Reserpine: a tragic victim of myths, marketing, and fashionable prescribing.Clin Pharmacol Ther. 1996 Oct;60(4):368-73. doi: 10.1016/S0009-9236(96)90193-9. Clin Pharmacol Ther. 1996. PMID: 8873684 Review. No abstract available.
-
[Reserpine and breast cancer].Wiad Lek. 1984 Mar 1;37(5):367-70. Wiad Lek. 1984. PMID: 6147937 Review. Polish. No abstract available.
Cited by
-
Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?J Gen Intern Med. 1991 Nov-Dec;6(6):561-72. doi: 10.1007/BF02598229. J Gen Intern Med. 1991. PMID: 1810301 Review. No abstract available.
-
Prolactin secretion during reserpine and syrosingopine treatment.Eur J Clin Pharmacol. 1981;20(5):347-9. doi: 10.1007/BF00615404. Eur J Clin Pharmacol. 1981. PMID: 6116608 Clinical Trial.
-
Carcinogenicity of antihypertensive therapy.Curr Hypertens Rep. 2002 Jun;4(3):195-201. doi: 10.1007/s11906-002-0007-4. Curr Hypertens Rep. 2002. PMID: 12003701 Review.